Abstract
Purpose
Imatinib often causes gastric upset resulting in frequent co-administration of an antacid. Elevated gastric pH, delayed gastric emptying, or introduction of Mg2+/Al3+ could potentially change imatinib absorption, thereby affecting the therapeutic effectiveness of imatinib. Indeed, antacid co-administration with dasatinib does result in a twofold decrease in dasatinib absorption. We aimed to define the effect of antacid on the pharmacokinetics of imatinib.
Methods
Twelve healthy subjects were enrolled in a 2-period, open-label, randomized cross-over, fixed-sequence study. In one period, each subject received 400 mg imatinib p.o., and in the other, the same dose of imatinib preceded by 20 mL antacid, containing 1.6 g Al(OH)3 + 1.6 g Mg(OH)2, 15 min before imatinib. Plasma concentrations of imatinib and its active N-desmethyl metabolite CGP74588 were determined by LC–MS, and data were analyzed non-compartmentally.
Results
Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 μg/(mL h) alone versus 32.6 μg/(mL h) with antacid, P = 0.37; 80% power].
Conclusions
Our results indicate that the use of Mg2+-Al3+-based antacid does not significantly affect imatinib absorption.
Similar content being viewed by others
References
Bristol-Myers Squibb Company (2007) Prescribing Information Sprycel(R) (dasatinib)
Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, KM U, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942
de Campos DR, Vieira NR, Bernasconi G, Barros FA, Meurer EC, Marchioretto MA, Coelho EC, Calafatti SA, Sommer C, Couto JM, Buranello S, Silva AR, Amarante AR, Abib E, Junior JP (2007) Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. Arzneimittelforschung 57:309–314
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ (2003) Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 791:39–44
Acknowledgments
We thank the nursing staff of the University of Pittsburgh Clinical Translational Research Center for their invaluable assistance, and the University of Pittsburgh Cancer Institute Hematology/Oncology Writing Group for constructive suggestions regarding the manuscript. This work was supported by Novartis Pharmaceuticals Corporation (East Hanover, NJ), and NIH/NCRR/CTSA Grant UL1 RR024153. WinNonlin software was provided as part of the Pharsight Academic Licensing Program.
Author information
Authors and Affiliations
Corresponding author
Additional information
WinNonlin software was provided as part of the Pharsight Academic Licensing Program.
Rights and permissions
About this article
Cite this article
Sparano, B.A., Egorin, M.J., Parise, R.A. et al. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63, 525–528 (2009). https://doi.org/10.1007/s00280-008-0778-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-008-0778-7